Impact of Angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series.

BACKGROUND Angiotensin II may be involved in amyloid metabolism in the brain. Angiotensin receptor blockers (ARBs) may also prevent cognitive decline. OBJECTIVE To evaluate the impact of treatment with ARBs on the neuropathology of Alzheimer disease (AD) in the National Alzheimer Coordinating Center database, which includes aggregated data and brain autopsies from 29 AD centers throughout the United States. DESIGN Multiple logistic regression was used to compare the pathologic findings in hypertensive subjects taking ARBs with those taking other antihypertensive treatments as well as with hypertensive subjects who did not receive antihypertensive medications. SETTING Neuropathologic data included neuritic plaque and neurofibrillary tangle measures and vascular injury markers. PATIENTS Data were collected from participants who were self-referred or provider-referred and included those with and without cognitive disorders. Our sample included only hypertensive participants and excluded cognitively and neuropathologically normal participants (N = 890; mean age at death, 81 years [range, 39-107 years]; 43% women; 94% white). RESULTS Participants with or without AD who were treated with ARBs showed less amyloid deposition markers compared with those treated with other antihypertensive medications (lower Consortium to Establish a Registry of Alzheimer Disease score: odds ratio, 0.47, 95% CI, 0.27-0.81; Alzheimer Disease and Related Disorders Association score: odds ratio, 0.43, 95% CI, 0.21-0.91; Braak and Braak stage: odds ratio, 0.52, 95% CI, 0.31-0.85; neuritic plaques: odds ratio, 0.59, 95% CI, 0.37-0.96). They also had less AD-related pathology compared with untreated hypertensive subjects. Participants who received ARBs were more likely to have had a stroke; hence, they had more frequent pathologic evidence of large vessel infarct and hemorrhage. CONCLUSION Treatment with ARBs is associated with less AD-related pathology on autopsy evaluations. The effect of ARBs on cognitive decline in those with dementia or AD needs further investigation.

[1]  A. Fleisher,et al.  Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons , 2012, Neurobiology of Aging.

[2]  C. Roe,et al.  Relationship Between Late-Life Hypertension, Blood Pressure, and Alzheimer’s Disease , 2011, American journal of Alzheimer's disease and other dementias.

[3]  D. Aarsland,et al.  Hypertension is a potential risk factor for vascular dementia: systematic review , 2011, International journal of geriatric psychiatry.

[4]  Z. Khachaturian.  Revised criteria for diagnosis of Alzheimer’s disease: National Institute on Aging-Alzheimer's Association diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[5]  Q. Tong,et al.  Central Angiotensin II Stimulation Promotes β Amyloid Production in Sprague Dawley Rats , 2011, PloS one.

[6]  M. Schwab,et al.  Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. , 2010, Rejuvenation research.

[7]  L. Farrer,et al.  Hypertension Increases the Probability of Alzheimer’s Disease and of Mild Cognitive Impairment in an Arab Community in Northern Israel , 2009, Neuroepidemiology.

[8]  V. Haroutunian,et al.  Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons , 2009, Neurology.

[9]  Wei Zhao,et al.  Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. , 2007, The Journal of clinical investigation.

[10]  Woodrow D. Deitrich,et al.  The National Alzheimer's Coordinating Center (NACC) Database: An Alzheimer Disease Database , 2004, Alzheimer disease and associated disorders.

[11]  D. Tomassoni,et al.  Arterial Hypertension: A Cause of Cognitive Impairment and of Vascular Dementia , 2004, Clinical and experimental hypertension.

[12]  A. Igarashi,et al.  Angiotensin-converting Enzyme Degrades Alzheimer Amyloid β-Peptide (Aβ); Retards Aβ Aggregation, Deposition, Fibril Formation; and Inhibits Cytotoxicity* , 2001, The Journal of Biological Chemistry.

[13]  D. Selkoe,et al.  Toward a Comprehensive Theory for Alzheimer's Disease. Hypothesis: Alzheimer's Disease Is Caused by the Cerebral Accumulation and Cytotoxicity of Amyloid β‐Protein , 2000, Annals of the New York Academy of Sciences.

[14]  H. Braak,et al.  Assessment of the Pathological Stages of Alzheimer’s Disease in Thin Paraffin Sections: A Comparative Study , 1998, Dementia and Geriatric Cognitive Disorders.

[15]  S. Mirra,et al.  Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists. , 1993, Archives of pathology & laboratory medicine.

[16]  G. Román,et al.  Senile dementia of the Binswanger type. A vascular form of dementia in the elderly. , 1987, JAMA.

[17]  W. Elliott.  Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis , 2011 .

[18]  C. You,et al.  No association between hypertension and risk for Alzheimer's disease: a meta-analysis of longitudinal studies. , 2011, Journal of Alzheimer's disease : JAD.

[19]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.